Bright Futures and Genomic Duties
By Jonathan Kahn, Biopolitical Times guest contributor
| 04. 20. 2011
A recent issue of Nature reviewed the accomplishments of the Human Genome Project 10 years after the grand announcement of the completion of the first draft of the human genome. With a cover declaring "The Future is Bright," the issue featured an article by Eric Green, the new director of National Human Genome Research Institute, and others [pdf] that was intended to "articulate a 2011 vision for the future of genomics research and describe the path towards an era of genomic medicine."
Understandably, the authors accentuate the positive and express both hope and enthusiasm for the future of genomic research. To realize the great promise of ongoing genomic research, they also identify several "imperatives for genomic medicine," specifically:
- Making genomics-based diagnostics routine
- Defining the genetic components of disease
- Comprehensive characterization of cancer genomes
- Practical systems for clinical genomic informatics
- The role of the human microbiome in health and disease
These are relatively unexceptional goals and certainly worthy of pursuit. To propel genomic research down this path, however, the authors also declare that "Effective genomics research needs continual, broad...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...